Overcoming the Limitations of Protein A: Evolution of Bacterial Protein-Based and Synthetic Affinity Ligands for High-Performance IgG Purification
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177618 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Larisa N Ikryannikova und 8 weiteren Autor:innen. Beteiligte Einrichtung: I.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russ…. Hauptthemen laut MEDLINE: Staphylococcal Protein A, Immunoglobulin G, Chromatography, Affinity, Bacterial Proteins. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GREENVAN, LLC, GREENVAN, LLC private investor.
Abstract (Originalsprache)
Monoclonal antibodies (mAbs) are widely used as therapeutic molecules for the treatment of serious diseases, primarily cancer. The market for mAbs is one of the fastest-growing segments of the biopharmaceuticals industry. Purification is a crucial stage in the production of mAbs. While staphylococcal protein A (SpA) affinity chromatography remains the gold standard in industrial mAb purification, its limitations—low alkaline stability and insufficient binding capacity of SpA, as well as the need for harsh acidic elution conditions—have driven extensive efforts for novel progressive affinity ligands. This review focuses on the development and performance of bacterial protein-based affinity resins for the purification of class G immunoglobulins (IgGs), including conventional proteins A and G, the promising protein L, and the more recently discovered protein M (from M. genitalium), each offering unique specificities for different antibody fragments and species. Hybrid ligands combining domains from multiple bacterial proteins are also discussed, along with next-generation synthetic alternatives such as affibodies, affimers, nanobodies, etc., as well as peptide-based or mixed-mode ligands. The key finding is that the reliable and time-tested resins like those based on protein A continue to dominate the market, although future trends also point toward smaller, more stable, and cost-effective synthetic ligands for specific applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- I.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russia.
- M.V. Lomonosov Institute of Fine Chemical Technologies, MIREA-Russian Technological University, Vernadskogo Pr. 86, 119571 Moscow, Russia.
- R-Pharm Group Pharmaceutical Company, 119421 Moscow, Russia.
- M.M. Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str. 16/10, 117437 Moscow, Russia.
ORCID-Profile: Tatiana D Melikhova
Förderung
- GREENVAN, LLC
- GREENVAN, LLC private investor
Zitieren
APA
Ikryannikova, L. N., Tereshin, M. N., Baskova, M. V., Telepenina, K. P., Gorokhovets, N. V., Bayzigitov, D. R., Gurylina, E. A., Stepanenko, V. N., & Melikhova, T. D. (2026). Overcoming the Limitations of Protein A: Evolution of Bacterial Protein-Based and Synthetic Affinity Ligands for High-Performance IgG Purification. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177618
Vancouver
Ikryannikova LN, Tereshin MN, Baskova MV, Telepenina KP, Gorokhovets NV, Bayzigitov DR, et al. Overcoming the Limitations of Protein A: Evolution of Bacterial Protein-Based and Synthetic Affinity Ligands for High-Performance IgG Purification. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177618
BibTeX
@article{Ikryannikova2026,
author = {Ikryannikova, Larisa N and Tereshin, Mikhail N and Baskova, Milena V and Telepenina, Kristina P and Gorokhovets, Neonila V and Bayzigitov, Daniel R and Gurylina, Eugenia A and Stepanenko, Vasiliy N and Melikhova, Tatiana D},
title = {Overcoming the Limitations of Protein A: Evolution of Bacterial Protein-Based and Synthetic Affinity Ligands for High-Performance IgG Purification},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177618}
}
EUVIMED